Less Is More: Developments in Nanotechnology for Antirestenosis Therapies

Abstract

Despite recent advancements in vascular disease treatments, thrombosis and poor long-term vessel patency remain significant barriers to effective endovascular intervention. Current balloon angioplasty and stenting techniques effectively restore acute blood flow in occluded vessels but have persistent limitations. Damage to the arterial endothelium caused by injury during catheter tracking triggers neointimal hyperplasia and the release of proinflammatory factors leading to increased risk of thrombosis and restenosis. Antirestenotic agents commonly delivered on angioplasty balloons and stents have lowered arterial restenosis rates, but the absence of cell type selectivity significantly delays critical endothelium repair. Targeted delivery of biomolecular therapeutics, coupled with engineered nanoscale excipients, has the potential to redefine cardiovascular interventions by improving long-term efficacy, limiting off-target effects, and reducing costs compared with conventional clinical standards of care. This review analyzes current forms of localized vascular drug delivery, emerging nanoscale therapeutic and excipient strategies, and provides recommendations for future areas of study to advance the treatment of vascular disease through innovations in nanotechnology.

Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis

“…Nanotechnology, for instance, offers the potential to enhance stent coatings and drug delivery systems, ultimately improving stent surface biocompatibility and drug release control. This advancement aims to reduce toxicity and enhance treatment efficacy, with the ultimate goal of decreasing the occurrence of ISR and late-stage vascular risk events ( 119 , 120 ). On the other hand, 3D printing technology provides the opportunity for individualized treatment options, crafting stents that match the patient's specific vascular characteristics ( 121 ).…”

Nanotechnology in development of next generation of stent and related medical devices: Current and future aspects

“…Nanoparticles, especially surface‐modified degradable lipid and polymeric formulations, play a crucial role as carriers for targeted delivery of these biomolecular therapies. Advancements in nanotechnology present promising opportunities to combat restenosis, lower reintervention rates, and reduce late‐stage adverse events after vascular procedures like angioplasty (Trepanier et al, 2023). Finally, nonpolymeric nanomaterials like titanium dioxide nanotubes and nitride coatings promote endothelial health and prevent SMC hyperproliferation (Karjalainen & Nammas, 2017; Ma et al, 2023).…”